NCT01404312: A reported trial by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT01404312 |
|---|---|
| Title | Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | May 23, 2012 |
| Completion date | Nov. 14, 2017 |
| Required reporting date | Nov. 14, 2018, midnight |
| Actual reporting date | Nov. 14, 2018 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |